Skip to Navigation Skip to Search Skip to Content
Search All Centers

Real-World Response to CLL Combination Therapies

Read Transcript Download/Print Transcript

Published on May 30, 2018

After demonstrating the combination of novel agents to treat chronic lymphocytic leukemia (CLL) in clinical trials, experts are sharing the promising results and the strategy’s influence on the CLL treatment landscape. On location at CLL Live in Niagara Falls, Canada, CLL expert Dr. Thomas Kipps from the University of California San Diego Medical Centerdiscusses recent data on combination therapy regimens, like venetoclax (Venclexta) and rituximab (Rituxan), and their impact on patients. Dr. Kipps explains how this approach compares to standard chemotherapy and its’ efficacy on remission rate, sustainability and progression. Tune in to find out more as CLL treatment research propels forward.

Featuring

You might also like

Transcript | Real-World Response to CLL Combination Therapies

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

Dr. Kipps:

So, yes, we have been able to observe higher rates of remission and higher rates in which the patients have no detectable minimal residual disease after therapy.  And recently we completed a study, the Marama study, which compared a popular regimen, bendamustine/rituximab with venetoclax and rituximab for patients who have relapsed CLL.  And the upshot there was that the venetoclax/rituximab-treated patients had a more robust response, they had a deeper response, and they appear to be having a longer progression-free survival before requiring additional therapy.  And it seems like the survival periods are favoring venetoclax and rituximab, too. 

So here we have an oral regimen, venetoclax, compared to an IV regimen, such as bendamustine (Treanda), on being your standard type chemotherapy, and it may, I think in my opinion, eliminate or replace bendamustine/rituximab as a go-to regimen.  And I think it's going to be a very important study in terms of governing how we manage our patients in the future. 

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.